Company
KymaThera
San Diego, California biotech founded in 2024. Developing K-1728, an oral pan-mutant selective PI3Kα inhibitor, for PI3Kα-mutant cancers and vascular malformations.
1 story
Regulatory News has published 1 story about KymaThera on 7 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 7 October 2026.
This page is generated from Regulatory News’ editorial coverage of KymaThera. It is not an advertisement.
On the record
- Company
- KymaThera, Inc. (privately held)
- Headquarters
- San Diego, California
- Founded
- 2024
- Regulator
- U.S. Food and Drug Administration (proceeds fund IND-enabling work and a Phase 1 trial of K-1728)
- Latest milestone
- $80 million Series B financing
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
